Evaluation of SCH51048 in an experimental model of pulmonary aspergillosis.
The efficacy of a novel triazole, SCH51048, was assessed with a murine model of pulmonary aspergillosis and was compared with those of SCH39304 and itraconazole. A wide range of doses of SCH51048 (5 to 50 mg/kg of body weight) was evaluated. Mortality was significantly delayed in mice treated with doses of 5 mg of SCH51048 per kg or greater in comparison with mortality in controls (P < 0.05). Both SCH51048 and SCH39304 at higher doses (30 and 50 mg/kg) reduced the number of viable Aspergillus fumigatus organisms in lung tissue (P < 0.05). In the present model, itraconazole neither delayed mortality nor significantly reduced the counts in tissue at the doses used. We conclude that SCH51048 is an effective therapy for murine pulmonary aspergillosis.
Allendoerfer
R
R
Department of Medicine, University of Texas Health Science Center at San Antonio, USA.
Loebenberg
D
D
Rinaldi
M G
MG
Graybill
J R
JR
D000666:Amphotericin B / Q000008:administration & dosage / Q000627:therapeutic use; D000818:Animals; D000935:Antifungal Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D001228:Aspergillosis / Q000188:drug therapy* / Q000382:microbiology / Q000401:mortality; D001232:Aspergillus fumigatus / Q000187:drug effects* / Q000254:growth & development / Q000302:isolation & purification; D015169:Colony Count, Microbial; D004305:Dose-Response Relationship, Drug; D004341:Drug Evaluation; D005260:Female; D017964:Itraconazole / Q000008:administration & dosage / Q000627:therapeutic use; D008172:Lung Diseases, Fungal / Q000188:drug therapy* / Q000401:mortality; D051379:Mice; D008807:Mice, Inbred BALB C; D008826:Microbial Sensitivity Tests; D015996:Survival Rate; D014230:Triazoles / Q000008:administration & dosage / Q000627:therapeutic use*
D000935:Antifungal Agents; C094161:SCH 51048; D014230:Triazoles; C056513:Sch 39304; D017964:Itraconazole; D000666:Amphotericin B